crispr介导的EGFR信号在肺癌中的调节

IF 2.4 Q3 Medicine

Cancer treatment and research communications Pub Date : 2025-01-01 DOI:10.1016/j.ctarc.2025.100992

Mobina Tabibian , Elahe Motevaseli , Soudeh Ghafouri-Fard

{"title":"crispr介导的EGFR信号在肺癌中的调节","authors":"Mobina Tabibian , Elahe Motevaseli , Soudeh Ghafouri-Fard","doi":"10.1016/j.ctarc.2025.100992","DOIUrl":null,"url":null,"abstract":"<div><div>Lung cancer is among the most common cancers and the leading source of cancer death. Inhibition of EGFR signaling by small-molecule tyrosine kinase inhibitors and monoclonal antibodies has provided new opportunities for treatment of this type of cancer. However, prognosis remained unfavorable due to the incidence of intrinsic or attained resistance. The advent of CRISPR/Cas9 technology has offered additional chances for cancer genome editing. This technology has been applied in the context of lung cancer research in order to minimize the effects of activating EGFR mutations. In the current manuscript, we address the application of CRISPR/Cas9 method in the modulation of EGFR signaling and its consequence in the treatment of lung cancer.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"45 ","pages":"Article 100992"},"PeriodicalIF":2.4000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CRISPR-mediated modulation of EGFR signaling in lung cancer\",\"authors\":\"Mobina Tabibian , Elahe Motevaseli , Soudeh Ghafouri-Fard\",\"doi\":\"10.1016/j.ctarc.2025.100992\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Lung cancer is among the most common cancers and the leading source of cancer death. Inhibition of EGFR signaling by small-molecule tyrosine kinase inhibitors and monoclonal antibodies has provided new opportunities for treatment of this type of cancer. However, prognosis remained unfavorable due to the incidence of intrinsic or attained resistance. The advent of CRISPR/Cas9 technology has offered additional chances for cancer genome editing. This technology has been applied in the context of lung cancer research in order to minimize the effects of activating EGFR mutations. In the current manuscript, we address the application of CRISPR/Cas9 method in the modulation of EGFR signaling and its consequence in the treatment of lung cancer.</div></div>\",\"PeriodicalId\":9507,\"journal\":{\"name\":\"Cancer treatment and research communications\",\"volume\":\"45 \",\"pages\":\"Article 100992\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer treatment and research communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468294225001285\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294225001285","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

肺癌是最常见的癌症之一，也是癌症死亡的主要原因。小分子酪氨酸激酶抑制剂和单克隆抗体对EGFR信号的抑制为治疗这种类型的癌症提供了新的机会。然而，由于内在或获得性耐药的发生率，预后仍然不利。CRISPR/Cas9技术的出现为癌症基因组编辑提供了额外的机会。这项技术已被应用于肺癌研究，以尽量减少激活EGFR突变的影响。在当前的手稿中，我们讨论了CRISPR/Cas9方法在EGFR信号调节中的应用及其在肺癌治疗中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

CRISPR-mediated modulation of EGFR signaling in lung cancer

Lung cancer is among the most common cancers and the leading source of cancer death. Inhibition of EGFR signaling by small-molecule tyrosine kinase inhibitors and monoclonal antibodies has provided new opportunities for treatment of this type of cancer. However, prognosis remained unfavorable due to the incidence of intrinsic or attained resistance. The advent of CRISPR/Cas9 technology has offered additional chances for cancer genome editing. This technology has been applied in the context of lung cancer research in order to minimize the effects of activating EGFR mutations. In the current manuscript, we address the application of CRISPR/Cas9 method in the modulation of EGFR signaling and its consequence in the treatment of lung cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer treatment and research communications Medicine-Oncology

CiteScore

4.30

自引率

0.00%

发文量

148

审稿时长

56 days

期刊介绍： Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.